Distribution and antimicrobial resistance profile of ESBLs-producing Escherichia coli
10.16718/j.1009-7708.2017.02.012
- VernacularTitle:产超广谱β内酰胺酶大肠埃希菌的分布特点及耐药性分析
- Author:
Suling HUANG
- Keywords:
Escherichia coli;
extended spectrum beta-lactamase;
antimicrobial resistance
- From:
Chinese Journal of Infection and Chemotherapy
2017;17(2):182-186
- CountryChina
- Language:Chinese
-
Abstract:
Objective? To?investigate?the?distribution?and?antibiotic?resistance?profile?of?the?extended-spectrum?β-lactamase-producing Escherichia coli (ESBL-EC) isolates during the period from 2012 to 2015. Methods ESBL-EC isolates were reviewed retrospectively from 2012 to 2015 and subjected to analysis with WHONET 5.6 software. Results A total of 725, 732, 760, and 770 ESBL-EC strains were isolated each year from 2012 to 2015. The isolates were mainly from urine, sputum, blood, drainage fluid, peritoneal fluid and bile. The ESBL-EC strains were mainly collected from the patients treated in departments of urology, hepatobiliary surgery, nephrology and gynecology. More than 90% of the ESBL-EC strains were resistant to ampicillin, cefazolin, cefuroxime,?and?ceftriaxone,?and?more?than?50?%?of?these?strains?were?resistant?to?trimethoprim-sulfamethoxazole,?ciprofloxacin,?levofloxacin,?and?aztreonam.?However,?less?than?15?%?of?the?ESBL-EC?isolates?were?resistant?to?amikacin,?nitrofurantoin,?cefotetan,?cefoperazone-sulbactam, piperacillin-tazobactam, amoxicinllin-clavulanic acid, ertapenem, imipenem, meropenem, and tigecycline. The resistance rate of ESBL-EC to cefoperazone-sulbactam, piperacillin-tazobactam, ertapenem, imipenem, and meropenem was increasing over time. Conclusions ESBL-EC isolates show extremely high resistance to the commonly used cephalosporins. Cefoperazone-sulbactam, piperacillin-tazobactam, ertapenem, imipenem, and meropenem are still active for these pathogens, even though increasing resistance rate is observed over time.
